199 related articles for article (PubMed ID: 9142315)
21. Management of Epstein-Barr virus-induced post-transplant lymphoproliferative disease in recipients of solid organ transplantation.
Green M
Am J Transplant; 2001 Jul; 1(2):103-8. PubMed ID: 12099356
[TBL] [Abstract][Full Text] [Related]
22. Post-transplant lymphoproliferative disorder after solid-organ transplant in children.
Absalon MJ; Khoury RA; Phillips CL
Semin Pediatr Surg; 2017 Aug; 26(4):257-266. PubMed ID: 28964482
[TBL] [Abstract][Full Text] [Related]
23. Donor Monoclonal Gammopathy May Cause Lymphoproliferative Disorders in Solid Organ Transplant Recipients.
Felldin M; Ekberg J; Polanska-Tamborek D; Hansson U; Sender M; Rizell M; Svanvik J; Mölne J
Am J Transplant; 2016 Sep; 16(9):2676-83. PubMed ID: 27575725
[TBL] [Abstract][Full Text] [Related]
24. Post-transplant lymphoproliferative disease in heart and lung transplantation: Defining risk and prognostic factors.
Kumarasinghe G; Lavee O; Parker A; Nivison-Smith I; Milliken S; Dodds A; Joseph J; Fay K; Ma DD; Malouf M; Plit M; Havryk A; Keogh AM; Hayward CS; Kotlyar E; Jabbour A; Glanville AR; Macdonald PS; Moore JJ
J Heart Lung Transplant; 2015 Nov; 34(11):1406-14. PubMed ID: 26279197
[TBL] [Abstract][Full Text] [Related]
25. Treatment of EBV-related post-renal transplant lymphoproliferative disease with a tailored regimen including EBV-specific T cells.
Comoli P; Maccario R; Locatelli F; Valente U; Basso S; Garaventa A; Tomà P; Botti G; Melioli G; Baldanti F; Nocera A; Perfumo F; Ginevri F
Am J Transplant; 2005 Jun; 5(6):1415-22. PubMed ID: 15888049
[TBL] [Abstract][Full Text] [Related]
26. Treatment of posttransplant lymphoproliferative disease in the central nervous system of a lung transplant recipient using allogeneic leukocytes.
Emanuel DJ; Lucas KG; Mallory GB; Edwards-Brown MK; Pollok KE; Conrad PD; Robertson KA; Smith FO
Transplantation; 1997 Jun; 63(11):1691-4. PubMed ID: 9197369
[TBL] [Abstract][Full Text] [Related]
27. Post-transplantation lymphoproliferative disorder in heart and kidney transplant patients: a single-center experience.
Wasson S; Zafar MN; Best J; Reddy HK
J Cardiovasc Pharmacol Ther; 2006 Mar; 11(1):77-83. PubMed ID: 16703222
[TBL] [Abstract][Full Text] [Related]
28. Post-transplant lymphoproliferative disorders: clinicopathological analysis of 43 cases in a single center, 1990-2009.
Yoon SO; Yu E; Cho YM; Suh C; Kim KM; Han DJ; Lee SG; Huh J
Clin Transplant; 2012; 26(1):67-73. PubMed ID: 21269330
[TBL] [Abstract][Full Text] [Related]
29. Posttransplant lymphoproliferative disorders in heart-lung transplant recipients: primary presentation in the allograft.
Yousem SA; Randhawa P; Locker J; Paradis IL; Dauber JA; Griffith BP; Nalesnik MA
Hum Pathol; 1989 Apr; 20(4):361-9. PubMed ID: 2539321
[TBL] [Abstract][Full Text] [Related]
30. Cytotoxic T-lymphocyte therapy for post-transplant lymphoproliferative disorder after solid organ transplantation in children.
Chiou FK; Beath SV; Wilkie GM; Vickers MA; Morland B; Gupte GL
Pediatr Transplant; 2018 Mar; 22(2):. PubMed ID: 29388302
[TBL] [Abstract][Full Text] [Related]
31. Late-onset post-transplant lymphoproliferative disease: a report of four patients in one center.
Ramadan KM; Bowers M; El-Agnaf MR; Kettle P
Leuk Lymphoma; 2006 Jun; 47(6):1191-3. PubMed ID: 16840223
[No Abstract] [Full Text] [Related]
32. Epstein-barr virus and posttransplant lymphoproliferative disorder in solid organ transplant recipients.
Allen U; Preiksaitis J;
Am J Transplant; 2009 Dec; 9 Suppl 4():S87-96. PubMed ID: 20070701
[No Abstract] [Full Text] [Related]
33. Treatment of Epstein-Barr virus-associated posttransplant lymphoproliferative disorders.
Gross TG
J Pediatr Hematol Oncol; 2001 Jan; 23(1):7-9. PubMed ID: 11196278
[No Abstract] [Full Text] [Related]
34. II. Challenges in the management of post-transplant lymphoproliferative disorder.
Nassi L; Gaidano G
Hematol Oncol; 2015 Jun; 33 Suppl 1():96-9. PubMed ID: 26062065
[No Abstract] [Full Text] [Related]
35. Radioimmunotherapy ((90) Y-Ibritumomab Tiuxetan) for Posttransplant Lymphoproliferative Disorders After Prior Exposure to Rituximab.
Rossignol J; Terriou L; Robu D; Willekens C; Hivert B; Pascal L; Guieze R; Trappe R; Baillet C; Huglo D; Morschhauser F
Am J Transplant; 2015 Jul; 15(7):1976-81. PubMed ID: 25868706
[TBL] [Abstract][Full Text] [Related]
36. [The importance of more research on post-transplant lymphoproliferative disorders in China].
Liu QF
Zhonghua Nei Ke Za Zhi; 2007 Dec; 46(12):977-8. PubMed ID: 18478909
[No Abstract] [Full Text] [Related]
37. Occurrence of post-transplant lymphoproliferative disorders among over thousand adult recipients: any role for hepatitis C infection?
Burra P; Buda A; Livi U; Rigotti P; Zanus G; Calabrese F; Caforio A; Menin C; Canova D; Farinati F; Luciana Aversa SM
Eur J Gastroenterol Hepatol; 2006 Oct; 18(10):1065-70. PubMed ID: 16957512
[TBL] [Abstract][Full Text] [Related]
38. Malignancies following lung transplantation.
Robbins HY; Arcasoy SM
Clin Chest Med; 2011 Jun; 32(2):343-55. PubMed ID: 21511094
[TBL] [Abstract][Full Text] [Related]
39. Epstein-Barr virus-negative lymphoproliferate disorders in long-term survivors after heart, kidney, and liver transplant.
Dotti G; Fiocchi R; Motta T; Gamba A; Gotti E; Gridelli B; Borleri G; Manzoni C; Viero P; Remuzzi G; Barbui T; Rambaldi A
Transplantation; 2000 Mar; 69(5):827-33. PubMed ID: 10755535
[TBL] [Abstract][Full Text] [Related]
40. Lymphoproliferative disease post-renal transplantation.
Newstead CG
Nephrol Dial Transplant; 2000 Dec; 15(12):1913-6. PubMed ID: 11096131
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
